OTCMKTS:INVVY

Indivior Stock Forecast, Price & News

$8.97

+0.03 (+0.34 %)

(As of 03/1/2021 12:00 AM ET)

Add

Compare

Today's Range

$8.95

Now: $8.97▼

$9.34

50-Day Range

$7.00

MA: $9.12▼

$10.50

52-Week Range

$2.23

Now: $8.97▼

$40.00

Volume2,803 shs

Average Volume12,241 shs

Market Capitalization$1.32 billion

P/E RatioN/A

Dividend YieldN/A

Beta0.3

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's products focuses on treating substance use disorder, opioid use disorder, and schizophrenia. It offers SUBLOCADE injection for subcutaneous use; SUBOXONE sublingual film; and PERSERIS for extended-release injectable suspension, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex. The company is also involved in finance activities. It operates in approximately 40 countries worldwide. Indivior PLC was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Headlines

BioXcel Therapeutics Appoints Javier Rodriguez as Chief Legal Officer and Corporate Secretary - StreetInsider.com
February 23, 2021 | streetinsider.com

Edited Transcript of INDV.L earnings conference call or presentation 18-Feb-21 12:00pm GMT - Yahoo Finance
February 19, 2021 | finance.yahoo.com

Indivior Swings To Annual Loss On Higher Costs And Lower Revenue
February 19, 2021 | lse.co.uk

PRECIOUS-Gold prices off 2-1/2-month low as U.S. Treasury yields pull back - Nasdaq
February 18, 2021 | nasdaq.com

Indivior PLC's (INVVY) CEO Mark Crossley on Q4 2020 Results - Earnings Call Transcript - Seeking Alpha
February 18, 2021 | seekingalpha.com

Economic Data Puts the EUR and Dollar in the Spotlight, with ECB Minutes also in Focus - Nasdaq
February 18, 2021 | nasdaq.com

Canada's Teck fourth-qtr adj profit soars on boost from copper business - Nasdaq
February 18, 2021 | nasdaq.com

FTSE 100 flat as downbeat Barclays earnings offset gains in mining stocks - Nasdaq
February 18, 2021 | nasdaq.com

Indivior Swings To Annual Loss On Higher Costs And Lower Revenue - Morningstar
February 18, 2021 | morningstar.co.uk

UPDATE 1-Drugmaker Indivior warns pandemic pain to extend into 2021 - Yahoo Finance
February 18, 2021 | finance.yahoo.com

Addex Provides Trading Update and Completes 2020 with Strong Cash Position of CHF18.7 million - StreetInsider.com
February 17, 2021 | streetinsider.com

Addex GABAB Positive Allosteric Modulator Demonstrates Promise in Alcohol Use Disorder - StreetInsider.com
February 16, 2021 | streetinsider.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange OTCMKTS

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolOTCMKTS:INVVY

Previous SymbolNASDAQ:INVVY

CUSIPN/A

CIKN/A

Webwww.indivior.com

Phone804-379-1090

Employees796

Year FoundedN/A

Debt

Debt-to-Equity Ratio2.89

Current Ratio1.82

Quick Ratio1.69

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E Ratio27.17

P/E GrowthN/A

Sales & Book Value

Annual Sales$785 million

Price / Sales1.68

Cash Flow$1.79 per share

Price / Cash Flow5.01

Book Value$1.43 per share

Price / Book6.27

Profitability

EPS (Most Recent Fiscal Year)$1.15

Net Income$134 million

Net Margins-31.93%

Return on Equity-4.15%

Return on Assets-0.26%

Miscellaneous

Outstanding Shares146,811,000

Market Cap$1.32 billion

Next Earnings Date3/4/2021 (Estimated)

OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

0.78 out of 5 stars

Medical Sector

1159th out of 1,965 stocks

Pharmaceutical Preparations Industry

530th out of 772 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Indivior.

2.0 Community Rank

Outperform Votes
Indivior has received 128 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Indivior has received 200 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Indivior has received 60.98% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Indivior and other stocks. Vote “Outperform” if you believe INVVY will outperform the S&P 500 over the long term. Vote “Underperform” if you believe INVVY will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Indivior does not currently pay a dividend.
Dividend Growth
Indivior does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Indivior insiders have not sold or bought any company stock.

1.9 Earnings and Valuation

Earnings Growth
Earnings for Indivior are expected to grow by 78.79% in the coming year, from $0.33 to $0.59 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Indivior is -6.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Indivior is -6.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Indivior has a P/B Ratio of 6.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

$8.97

+0.03 (+0.34 %)

(As of 03/1/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive INVVY News and Ratings via Email

Sign-up to receive the latest news and ratings for INVVY and its competitors with MarketBeat's FREE daily newsletter.

Indivior (OTCMKTS:INVVY) Frequently Asked Questions

Is Indivior a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Indivior in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Indivior stock.
View analyst ratings for Indivior or view top-rated stocks.

What stocks does MarketBeat like better than Indivior?

Wall Street analysts have given Indivior a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Indivior wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Indivior's next earnings date?

Indivior is scheduled to release its next quarterly earnings announcement on Thursday, March 4th 2021.
View our earnings forecast for Indivior.

How has Indivior's stock price been impacted by COVID-19?

Indivior's stock was trading at $2.84 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, INVVY stock has increased by 215.7% and is now trading at $8.9654.
View which stocks have been most impacted by COVID-19.

Who are Indivior's key executives?

Indivior's management team includes the following people:

Mr. Mark Crossley, CEO & Exec. Director
Mr. Ryan Preblick, CFO & Exec. Director
Dr. Christian Heidbreder, Chief Scientific Officer
Mr. Jason Thompson, VP of Investor Relations
Ms. Cynthia Cetani, Chief Integrity & Compliance Officer
Mr. Jon Fogle, Chief HR Officer
Mr. Richard Simkin, Chief Commercial & Strategy Officer
Ms. Sue Learned, Sr. VP of Global Clinical Devel.
Hillel West, Chief Manufacturing & Supply Officer
Ms. Kathryn Hudson, Company Sec.

Who are some of Indivior's key competitors?

Some companies that are related to Indivior include Biohaven Pharmaceutical (BHVN), Sage Therapeutics (SAGE), Arena Pharmaceuticals (ARNA), Eidos Therapeutics (EIDX), ChemoCentryx (CCXI), I-Mab (IMAB), FibroGen (FGEN), Hutchison China MediTech (HCM), Reata Pharmaceuticals (RETA), Nektar Therapeutics (NKTR), PTC Therapeutics (PTCT), Insmed (INSM), Arvinas (ARVN), Hypera (HYPMY) and Apellis Pharmaceuticals (APLS).
View all of INVVY's competitors.

What is Indivior's stock symbol?

Indivior trades on the OTCMKTS under the ticker symbol "INVVY."

How do I buy shares of Indivior?

Shares of INVVY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Indivior's stock price today?

One share of INVVY stock can currently be purchased for approximately $8.97.

How much money does Indivior make?

Indivior has a market capitalization of $1.32 billion and generates $785 million in revenue each year. The company earns $134 million in net income (profit) each year or $1.15 on an earnings per share basis.

How many employees does Indivior have?

Indivior employs 796 workers across the globe.

What is Indivior's official website?

The official website for Indivior is www.indivior.com.

Where are Indivior's headquarters?

Indivior is headquartered at 10710 Midlothian Turnpike, North Chesterfield VA, 23235.

How can I contact Indivior?

Indivior's mailing address is 10710 Midlothian Turnpike, North Chesterfield VA, 23235. The company can be reached via phone at 804-379-1090 or via email at [email protected]

This page was last updated on 3/1/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here